All Trials
-
ATLAS 2
- Cardiology
- PHASE III
- 13,570 participants
- 8 sites in New Zealand
- 800 sites globally
ATLAS ACS 2 TIMI 51 (The second trial of Anti-Xa Therapy to Lower cardiovascular events in Addition to standard therapy in Subjects with Acute Coronary Syndrome)
A randomised, double-blind, placebo-controlled, event-driven multicenter study to evaluate the efficacy and safety of Rivaroxaban in subjects with a recent acute coronary syndrome.
This is a randomised, double-blind, placebo-controlled, event driven multicenter study to evaluate the efficacy and safety of Rivaroxaban in subjects with a recent acute coronary syndrome. The purpose is to determine whether Rivaroxaban in addition to standard care reduces the risk of the composite cardiovascular (CV) death, myocardial infarction (MI) or stroke in participants with a recent ACS compared with placebo in addition to standard care.
More about the ATLAS 2 study -
CURRENT / OASIS-7
- Cardiology
- PHASE III
- 18,000 participants
- 7 sites in New Zealand
- 600-800 sites globally
Randomised, multinational, double-blind study, comparing a high loading dose regimen of clopidogrel versus standard dose in patients with unstable angina or non-ST segment elevation myocardial infarction managed with an early invasive strategy
This is a phase III, multinational, multicentre, randomised, factorial design, parallel-group study comparing 2 regimens of clopidogrel (high versus standard dose) in a double-blind fashion and 2 regimens of aspirin (high versus low dose) in an open-label fashion in participants with symptoms of acute coronary disease who undergo a percutaneous coronary intervention as early as possible within 24 hours.
For further information, please visit http://clinicaltrials.gov/ct2/show/NCT00335452?term=NCT00335452&rank=1
More about the CURRENT / OASIS-7 study -
IMPROVE-IT
- Cardiology
- PHASE IIIb
- 18,000 participants
- 8 sites in New Zealand
- 1,500 sites globally
IMPROVE IT – IMProved Reduction of Outcomes: Vytorin Efficacy International Trial.
A Multicentre, Double-Blind, Randomised Study to Establish the Clinical Benefit and Safety of Vytorin (Ezetimibe/Simvastatin Tablet) vs Simvastatin Monotherapy in High-Risk Subjects Presenting With Acute Coronary Syndrome.
The main aim of the trial is to evaluate the benefit of Vytorin (study medication) compared to Simvastatin (control therapy) in participants who have experienced a heart attack or chest pain which required treatment in a hospital. This is a phase IIIb trial meaning that both of the medications that will be used in the trial have been approved by the government for use by doctors in New Zealand.
More about the IMPROVE-IT study -
RESDIO AP
- Device
- PHASE
- 300 participants
- 4 sites in New Zealand
- 1 site in Australia
Randomised Controlled Trial Evaluating Safety of Device Implantation in Orally Anticoagulated Patients (RESDIO-AP trial).
A randomised, single-blinded, controlled trial comparing device implantation in patients with therapeutic levels of anticoagulation (INR 2.0-3.0) to those with an INR <1.5 at the time of the surgical procedure.
This is a randomised, single blinded, controlled trial comparing device implantation in participants with therapeutic levels of anticoagulation (INR 2.0-3.0) to those with an INR <1.5 at the time of the surgical procedure. The purpose of this study is to prospectively evaluate the safety and efficacy of device implantation in patients with therapeutic levels of anticoagulation (INR 2.0-3.0) in a multi-centre randomised controlled trial. The study is to be conducted at 5 centres located in NZ and Australia.
More about the RESDIO AP study -
ROCKET AF
- Cardiology
- PHASE III
- 14,000 participants
- 7 sites in New Zealand
Study Comparing Rivaroxaban (study drug) with Warfarin in patients being treated for non-Valvular Atrial Fibrillation.
A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) with Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects with Non-Valvular Atrial Fibrillation.
The main aim of this study is to demonstrate that rivaroxaban (study drug), a direct factor Xa inhibitor, is as good as the standard treatment warfarin for the prevention of thromboembolic events in subjects with non-valvular atrial fibrillation.
More about the ROCKET AF study -
STABILITY
- Cardiology
- PHASE III
- 15,500 participants
- 12 sites in New Zealand
- 39 participating countries
STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY
A Multi-centre, Randomised, Double-Blind, Placebo-controlled, Event-driven Study of Darapladib versus Placebo in Subjects with Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE).
This is a phase III randomized, multi-centre, placebo-controlled, double-blind, parallel group, event-driven study involving an investigational drug darapladib (SB-480848). This study will compare the chronic effects of darapladib versus placebo when added to the standard of care, on the incidence of major adverse cardiovascular events (MACE) in high risk patients with chronic Coronary Heart Disease (CHD).
More about the STABILITY study -
STICH
- Surgical
- PHASE III & IV
- 2,425 participants
- 125 sites globally
Surgical Treatment for Ischemic Heart Failure (STICH) Trial is a multicentre, international, randomised trial comparing medical treatment + CABG, and medical treatment + CABG + surgical ventricular restoration (SVR) in 2,425 patients. Follow -up will be between 2 to 6 years.
More about the STICH study -
TECOS
- Diabetes
- PHASE III
- 14,000 participants
- 12 sites in New Zealand
- 36 participating countries
TECOS: Trial Evaluating Cardiovascular Outcomes with Sitagliptin
A randomised, placebo controlled clinical Trial to Evaluate Cardiovascular Outcomes after treatment with Sitagliptin in patients with Type 2 Diabetes Mellitus and inadequate glycemic control on mono-or dual combination oral antihyperlycemic therapy (TECOS)
This is a multinational, placebo-controlled, double-blind, randomised, parallel-group pragmatic clinical trial. The purpose of this study is to assess the impact of sitagliptin therapy upon cardiovascular (CV) outcomes in a large population from a diverse group of countries and practice environments.
More about the TECOS study -
TRACER
- Cardiology
- PHASE III
- 10,000 participants
- 12 sites in New Zealand
- 800 sites globally
A Multi-centre, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects With Acute Coronary Syndrome: Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA•CER)
This is a phase III randomised, multicentre, double-blind, placebo-controlled, balanced-parallel-groups study involving the use of an investigational drug SCH 530348. This study will evaluate the safety and efficacy of SCH 530348 in addition to the standard of care in participants with atherosclerotic disease/acute coronary syndrome (ACS) and determine if there is a clinical benefit relative to standard of care alone.
More about the TRACER study